Antibiotic Review at 48–72 Hours Audit

Free projects are complete and ready to use. Paid projects can also be adapted to your local requirements. This project uses a fixed Lazomis clinical configuration of 21 audit criteria across initial antimicrobial documentation, allergy and safety checks, review timing, clinical response and microbiology review, antimicrobial decision-making, IV-to-oral switch and duration, specialist advice and restrictions, and discharge and transfer communication. Data collection, dashboards, findings, improvement planning, re-audit and every output are included at no cost.

• Ward pharmacists and antimicrobial stewardship teams
• Doctors, ACPs and PAs
• Microbiology and infection teams
• Governance and Audit leads

• Measure documentation of indication, allergy status and review plan
• Assess completion of antibiotic review at 48–72 hours
• Review microbiology results, IV-to-oral switch and duration decisions
• Generate governance-ready antimicrobial stewardship evidence

• Anonymised case identifier
• Care setting and antibiotic review context
• Route at review and review outcome
• Review, decision and duration documentation

• Live dashboard
• Audit report (Word)
• Executive summary (Word)
• Excel workbook
• PowerPoint presentation
• Conference poster
• ARCP evidence summary

• Designed to use anonymised or pseudonymised audit identifiers.
• This tool supports, but does not replace, clinical judgement.
• Local policy, formulary and specialist advice should be followed.
• Organisations remain responsible for local governance arrangements.
• This audit tool supports antibiotic review documentation and antimicrobial stewardship quality improvement. It does not replace clinical judgement, local antimicrobial guidelines, microbiology advice, prescribing guidance, sepsis pathways or emergency escalation pathways.
• Audit data alone cannot support conclusions about inappropriate prescribing, medication harm, preventability, causality, policy breach or professional misconduct.
• Antibiotic choice, dose, duration, review timing and IV-to-oral switch criteria are set by national guidance and local policy and are not defined by this tool.
• Use anonymous case identifiers only — never patient-identifiable information.

Supporting guidance from the Lazomis QI Resource Library. Authoritative clinical standards referenced by this project remain separate.

• Patient SafetyMedicines Safety: A Systems Approach to Reducing HarmThis guide moves beyond individual error, explaining how a systems-based approach can fundamentally improve medicines safety across the NHS and reduce patient harm by addressing underlying contributing factors.
• Patient SafetyLeveraging Safety Data for Continuous Improvement in the NHSThis article outlines a practical framework for NHS teams to effectively utilise safety data, moving beyond mere collection to tangible improvements in patient care. It focuses on identifying, understanding, and addressing patient safety concerns through systematic data analysis.
• Clinical AuditCrafting Effective Executive Summaries for Clinical AuditsThis guide provides practical advice for UK clinicians on writing clear, concise, and impactful executive summaries for clinical audit reports, ensuring key messages reach busy NHS stakeholders.
• Clinical GovernanceClinical Governance Explained: A Framework for Quality and Safety in the NHSThis article defines clinical governance, outlines its key pillars, and explains why a robust framework is crucial for maintaining and improving patient safety and quality of care within the NHS.